Search

Your search keyword '"Fernández-Montolí, Maria Eulalia"' showing total 6 results
Start Over Author "Fernández-Montolí, Maria Eulalia"
6 results on '"Fernández-Montolí, Maria Eulalia"'

1. Impact of Excision Type, Cone Volume, and Dimensions on Persistence/Recurrence of Cervical Intraepithelial Neoplasia 2–3.

Author

Medina Bueno, Gonzalo Arturo, Fernández-Montolí, Maria Eulalia, Heydari, Fatima, Ponce, Jordi, Tous, Sara, and Peñafiel, Judith

Subjects
*CERVICAL intraepithelial neoplasia, *HUMAN papillomavirus, *SURGICAL margin, *VIRAL load, *CONES
Abstract

The objective of this study was to evaluate the relationship between the excision type and the persistence/recurrence of CIN2–3. A total of 227 women with CIN2–3 who were treated with LLETZ were evaluated. The types of excision according to the IFCPC 2011, volume, cone dimensions, margins of resection, post-cone high-risk human papillomavirus (HR-HPV) status, and viral load were studied. The time to recurrence was assessed using Kaplan–Meier curves. Persistent/recurrent CIN2–3 was found in 12 cases (5.2%). Type 1 excision was performed in 107 patients, with 7 recurrences (6.5%); type 2 excision in 74 patients, with 4 recurrences (5.4%); and type 3 excision in 46 patients, with 1 recurrence (2.1%). The percentage of clear margins in type 1 excisions was 44.9%, that in type 2 excisions was 59.5%, and that in type 3 excisions was 69.6% (p = 0.008). Type 1 excision was associated with 28.5% post-LLETZ HR-HPV positivity, that in type 2 reached 20.6%, and that in type 3 reached 11.4%; this difference was non-significant (p = 0.24). (4) Conclusions: Type 3 excision was associated with a larger proportion of clear margins and lower post-cone HR-HPV positivity, with a lower incidence of the persistence/recurrence of CIN2–3. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. The Shift From Sentinel Lymph Node Biopsy Performed Either Before or After Neoadjuvant Systemic Therapy in the Clinical Negative Nodes of Breast Cancer Patients. Results, and the Advantages and Disadvantages of Both Procedures

Author

Fernandez-Gonzalez, Sergi, Falo, Catalina, Pla, Maria Jesus, Pernas, Sonia, Bajen, Maite, Soler, Teresa, Ortega, Raul, Quetglas, Cecilia, Perez-Martin, Xavier, Fernandez Montoli, Maria Eulalia, Campos, Miriam, Varela-Rodriguez, Mar, Ponce, Jordi, and Garcia-Tejedor, Amparo

Published
2018
Full Text
View/download PDF

4. Fertility-Sparing Approaches in Atypical Endometrial Hyperplasia and Endometrial Cancer Patients : Current Evidence and Future Directions

Author

Contreras, Nayanar-Adela, Sabadell, Jordi, Verdaguer, Paula, Julià, Carla, Fernández-Montolí, Maria-Eulalia, Universitat Autònoma de Barcelona, Universitat de Barcelona, Institut d'Investigació Biomèdica de Bellvitge, Contreras, Nayanar-Adela, Sabadell, Jordi, Verdaguer, Paula, Julià, Carla, Fernández-Montolí, Maria-Eulalia, Universitat Autònoma de Barcelona, Universitat de Barcelona, and Institut d'Investigació Biomèdica de Bellvitge

Abstract

Endometrial cancer (EC) is the fourth most common cancer in women in developed countries. Although it is usually diagnosed in postmenopausal women, its incidence has increased in young women, as well in recent decades, with an estimated rate of 4% in those under 40 years of age. Factors involved in this increase, particularly in resource-rich countries, include delayed childbearing and the rise in obesity. The new molecular classification of EC should help to personalize treatment, through appropriate candidate selection. With the currently available evidence, the use of oral progestin either alone or in combination with other drugs such as metformin, levonorgestrel-releasing intrauterine devices and hysteroscopic resection, seems to be feasible and safe in women with early-stage EC limited to the endometrium. However, there is a lack of high-quality evidence of the efficacy and safety of conservative management in EC. Randomized clinical trials in younger women and obese patients are currently underway.

Published
2022

5. Fertility-Sparing Approaches in Atypical Endometrial Hyperplasia and Endometrial Cancer Patients: Current Evidence and Future Directions

Author

Contreras, Nayanar-Adela, Sabadell, Jordi, Verdaguer, Paula, Julià, Carla, Fernández-Montolí, Maria-Eulalia, Universitat Autònoma de Barcelona, Universitat de Barcelona, and Institut d'Investigació Biomèdica de Bellvitge

Subjects
Fecunditat humana, Organic Chemistry, Endometrial hyperplasia, Fertility Preservation, General Medicine, Levonorgestrel, Catalysis, Computer Science Applications, Endometrial Neoplasms, Inorganic Chemistry, Meta-analysis, Organ sparing treatments, Endometrial cancer, Human fertility, Càncer d'endometri, Endometrial Hyperplasia, Humans, Female, Randomized clinical trials, Physical and Theoretical Chemistry, Progestins, Fertility preservation, Molecular Biology, Endometrial neoplasms, Spectroscopy
Abstract

Endometrial cancer (EC) is the fourth most common cancer in women in developed countries. Although it is usually diagnosed in postmenopausal women, its incidence has increased in young women, as well in recent decades, with an estimated rate of 4% in those under 40 years of age. Factors involved in this increase, particularly in resource-rich countries, include delayed childbearing and the rise in obesity. The new molecular classification of EC should help to personalize treatment, through appropriate candidate selection. With the currently available evidence, the use of oral progestin either alone or in combination with other drugs such as metformin, levonorgestrel-releasing intrauterine devices and hysteroscopic resection, seems to be feasible and safe in women with early-stage EC limited to the endometrium. However, there is a lack of high-quality evidence of the efficacy and safety of conservative management in EC. Randomized clinical trials in younger women and obese patients are currently underway.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results